Friday, June 2, 2:45 PM–5:45 PM CDT
Oral Abstract Session
Central Nervous System Tumors

2008 Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study. O Iliopoulos, ABB Iversen, K Beckermann, et al

Take-Home Message

• LITESPARK-004 is an ongoing single-arm phase II study evaluating the HIF-2α inhibitor belzutifan. The study thus far has shown clinically meaningful activity in VHL-associated RCC, pheochromocytomas, and pancreatic neuroendocrine tumors. Here, the investigators report the updated results for the subgroup of participants with CNS hemangioblastomas.
• Belzutifan induced the shrinkage of VHL-disease–related CNS hemangioblastomas, regardless of the presence of cysts. The findings are consistent with those in other VHL disease–related lesions, with steady, lasting activity with over 3 years of treatment.

Saturday, June 3, 2023; 1:15 PM–4:15 PM CDT
Poster Session
Central Nervous System Tumors

2078 Belzutifan treatment of Von Hippel-Lindau (VHL) related central nervous system (CNS) hemangioblastomas (HBs): A single institution experience. O Iliopoulos, O Rapalino, FG Barker, et al

Take-Home Message

• This presentation reports the real-world results of a single-institution study of patients with VHL-associated CNS hemangioblastomas treated with the HIF-2α inhibitor belzutifan. At the point of analysis, 19 patients had been treated. Median follow-up was 12 months.
• The response rate in terms of both solid and cystic components of the hemangioblastomas was high, confirming clinical trial findings. No grade ≥3 toxicity or CDr. NS toxicity was reported during treatment.

Friday, June 2, 2023; 2:45 PM–5:45 PM CDT
Oral Abstract Session
Central Nervous System Tumors

2001 Evaluating the diagnostic performance of 18F-fluciclovine for detection of recurrent brain metastases after radiation therapy: Results from a prospective phase 2 trial. R Kotecha, V Chiang, M Tom, et al

Take-Home Message

• 18F-fluciclovine was studied in this prospective multicenter trial to evaluate its effectiveness in diagnosing suspected recurrence of brain metastasis following radiation therapy.
• The qualitative and quantitative image interpretation criteria established in this study for recurrent brain metastasis showed the agent to be a highly effective diagnostic tool, laying the groundwork for future evaluation into its diagnostic performance.

2005 Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study. AF Carpentier, C Verlut, F Ghiringhelli, et al

Take-Home Message

• This phase IIa trial was designed to test the efficacy and safety of UCCPvax, a therapeutic anti-telomerase vaccine, in patients with newly diagnosed glioblastomas. Participants were started on UCPvax 1 month after completion of concomitant radiation therapy and temozolomide. All of the 31 patients received at least one vaccination, and the vaccinations were given on average of 4.5 months. No grade 3–4 toxicity from the vaccine was reported. Progression-free and overall survivals were 8.9 and 17.9 months, respectively; 26% of the patients remained alive 2 years after glioblastoma diagnosis.
• In a population of poor-prognosis patients with unmethylated MGMT glioblastoma, UCPvax was found to be highly immunogenic.

Saturday, June 3, 2023; 1:15 PM–4:15 PM CDT
Poster Session
Central Nervous System Tumors

2032 Risk of brain metastases in metastatic non-small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from three randomized clinical trials involving first-line atezolizumab treatment. Y Zhou, JJ Ni, Z Zhu, Z Zhang

2047 Final results of phase 2 trial of personal dendritic cell (DC) vaccines loaded with autologous tumor antigens (ATA) in newly diagnosed glioblastoma (GBM). D Bota, D Piccioni, T Taylor, et al

2055 New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS). O Mirallas, G Velilla, F Ruiz-Pace, et al

2064 Ultrasensitive detection and monitoring of central nervous system tumors from plasma using personalized whole-genome ctDNA profiling. I Tran, K Galbraith, SL Gardner, et al

2067 Phase I study of BTK inhibitor ibrutinib with temozolomide and radiation in newly-diagnosed glioblastoma (EQUILIBRIUM): Final trial report. MS Ahluwalia, A Ozair, AA Khosla, et al

Saturday, June 3, 2023; 4:30 PM–6:00 PM CDT
Poster Discussion Session
Central Nervous System Tumors

2016 Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419). M Weller, J Felsberg, D Gramatzki, et al

Sunday, June 4, 2023; 1:00 PM–4:00 PM CDT
Plenary Session

LBA1 INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation. I Mellinghoff, M van den Bent, D Blumenthal, et al

Take-Home Message

• This is probably the most important trial result and advancement since the 2015/17 publications of TTFields.

ASCO 2023, aanbevolen abstracten, Ziekte van Von Hippel-Lindau, Dr. Amit Tirosh, disease–associated central nervous system (CNS), hersentumoren, dr. Roger Stupp

---

• ASCO 2023: aanbevolen abstracten gerelateerd aan de ziekte van Von Hippel-Lindau en disease–associated central nervous system (CNS) door wereldwijd bekende artsen en oncologen

---

• Peptide receptor radionuclidetherapie (PRRT) met Lutetium-177 geeft uitstekende resultaten bij patienten met gevorderde uitgezaaide neuro-endocriene tumoren met verbetering van mediane overleving van 12 maanden (48 vs 36 maanden)

---

• FDA geeft goedkeuring aan Sutent - sunitinib om dit medicijn te gebruiken voor endocriene pancreas tumoren na goede resultaten uit afgebroken fase III studie

---

• Tumoren in ruggenmerg en wervelkolom (algemeen)

---

• Ook mannen hebben opvliegers. Een boek over neuro-endocriene tumoren